209 related articles for article (PubMed ID: 38030572)
1. Immunosuppression in solid organ-transplant recipients and impact on nutrition support.
Wilson NK; Kataria AD
Nutr Clin Pract; 2024 Feb; 39(1):109-116. PubMed ID: 38030572
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression in uterus transplantation: from transplant to delivery.
D'Amico G; Del Prete L; Eghtesad B; Hashimoto K; Miller C; Tzakis A; Quintini C; Falcone T
Expert Opin Pharmacother; 2023 Jan; 24(1):29-35. PubMed ID: 35723045
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive drugs and associated complications in abdominal organ transplantation.
Olson JC
Curr Opin Crit Care; 2022 Apr; 28(2):208-215. PubMed ID: 35142726
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-targeted therapy for the management of solid organ transplant recipients.
Szczepanik A; Iasella CJ; McDyer JF; Ensor CR
Hum Immunol; 2019 Mar; 80(3):184-190. PubMed ID: 30562564
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
6. Top 10 Things Primary Care Physicians Should Know About Maintenance Immunosuppression for Transplant Recipients.
Lien YH
Am J Med; 2016 Jun; 129(6):568-72. PubMed ID: 26714210
[TBL] [Abstract][Full Text] [Related]
7. Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients.
Smedman TM; Line PD; Guren TK; Dueland S
Acta Oncol; 2018 Oct; 57(10):1414-1418. PubMed ID: 29912605
[No Abstract] [Full Text] [Related]
8. [Modern immunosuppression after solid organ transplantation].
Beimler J; Morath C; Zeier M
Internist (Berl); 2014 Feb; 55(2):212-22. PubMed ID: 24518922
[TBL] [Abstract][Full Text] [Related]
9. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation.
Nelson J; Alvey N; Bowman L; Schulte J; Segovia MC; McDermott J; Te HS; Kapila N; Levine DJ; Gottlieb RL; Oberholzer J; Campara M
Pharmacotherapy; 2022 Aug; 42(8):599-633. PubMed ID: 36032031
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression in the pediatric transplant recipient.
Blondet NM; Healey PJ; Hsu E
Semin Pediatr Surg; 2017 Aug; 26(4):193-198. PubMed ID: 28964473
[TBL] [Abstract][Full Text] [Related]
11. Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.
Mellon L; Doyle F; Hickey A; Ward KD; de Freitas DG; McCormick PA; O'Connell O; Conlon P
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD012854. PubMed ID: 36094829
[TBL] [Abstract][Full Text] [Related]
12. [Pulmonary infections following solid organ transplantation].
Müller V; Kováts Z; Horváth G
Orv Hetil; 2012 Jun; 153(23):899-903. PubMed ID: 22668590
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol.
Schuurmans MM; Raeber ME; Roeder M; Hage R
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984489
[TBL] [Abstract][Full Text] [Related]
14. Malignancy: An Adverse Effect of Immunosuppression.
Munagala M; Phancao A
Handb Exp Pharmacol; 2022; 272():315-335. PubMed ID: 34697663
[TBL] [Abstract][Full Text] [Related]
15. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and International Society for Heart and Lung Transplantation: An executive summary.
Nelson J; Alvey N; Bowman L; Schulte J; Segovia MC; McDermott J; Te HS; Kapila N; Levine DJ; Gottlieb RL; Oberholzer J; Campara M
Pharmacotherapy; 2022 Aug; 42(8):594-598. PubMed ID: 35810342
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006.
Na R; Laaksonen MA; Grulich AE; Webster AC; Meagher NS; McCaughan GW; Keogh AM; Vajdic CM
Clin Transplant; 2015 Nov; 29(11):978-90. PubMed ID: 26278925
[TBL] [Abstract][Full Text] [Related]
17. Management of dyslipidemia in adult solid organ transplant recipients.
Warden BA; Duell PB
J Clin Lipidol; 2019; 13(2):231-245. PubMed ID: 30928441
[TBL] [Abstract][Full Text] [Related]
18. Update on immunosuppressive drugs used in solid-organ transplantation and their nutrition implications.
McPartland KJ; Pomposelli JJ
Nutr Clin Pract; 2007 Oct; 22(5):467-73. PubMed ID: 17906270
[TBL] [Abstract][Full Text] [Related]
19. Synbiotics, prebiotics and probiotics for solid organ transplant recipients.
Cooper TE; Scholes-Robertson N; Craig JC; Hawley CM; Howell M; Johnson DW; Teixeira-Pinto A; Jaure A; Wong G
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014804. PubMed ID: 36126902
[TBL] [Abstract][Full Text] [Related]
20. Solid Organ Transplantation and Survival among Individuals with a History of Cancer.
Engels EA; Haber G; Hart A; Lynch CF; Li J; Pawlish KS; Qiao B; Yu KJ; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1312-1319. PubMed ID: 33926864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
